Ligand Targretin Symptom Trial Could Support Use For Early CTCL
A trial focusing on symptom improvement of cutaneous T-cell lymphoma patients could demonstrate the utility of Ligand's Targretin for patients with early stage CTCL, FDA's Oncologic Drugs Advisory Committee said Dec. 13.
You may also be interested in...
The approval of Targretin capsules is the second step in Ligand's plan to offer patients with cutaneous T-cell lymphoma treatment options for all stages of the disease. The company currently markets Ontak and recently submitted an NDA for Targretin Gel.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011